Press Releases

Amarantus Announces Three Data Presentations Related to the Company's LymPro Diagnostic Test at the Alzheimer's Association International Conference (AAIC)

SAN FRANCISCO and GENEVA, July 7, 2014 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that analytical performance, clinical performance and 6-year longitudinal data related to the Company's LymPro Test® will be presented at the Alzheimer's Association International Conference (AAIC), held at the Bella Center in Copenhagen, Denmark, July 12-17, 2014.

"We are pleased to be presenting data on three critical aspects of LymPro's diagnostic profile," said Gerald E. Commissiong, President & CEO of Amarantus. "It is critical to properly position LymPro within the scientific community as we advance towards commercialization. We believe this data will provide the basis for pharmaceutical companies to use LymPro initially as a surrogate marker in their trials and for Key Opinion Leaders to add LymPro as a tool in their diagnostic paradigm. These key constituents will be critical for LymPro's initial market adoption."

Poster Presentation Details
Date: July 14 2014
Location: Exhibit Hall (Bella Center Convention Center)
Poster Session Time: 11:45a.m. - 2:15 p.m.
Session Type: AAIC Poster Presentation
Proposal Number: 45402
Presentation Title: Employing Lymphocyte Proliferation as a means to Asses Cell Cycle Dys-regulation in Cognitively Impaired Subjects: Clinical Performance of the LymPro Assay
Poster Number: P2-389
Date: July 15, 2014
Location: Exhibit Hall (Bella Center Convention Center)
Poster Session Time: 11:45 a.m. – 2:15 p.m.
Session Type: AAIC Poster Presentation
Proposal Number: 45240
Presentation Title: Retrospective Analysis of Clinical Prognosis of Subjects from a 2008 study using the LymPro assay
Poster Number: P3-118
Date: July 15, 2014
Location: Exhibit Hall (Bella Center Convention Center)
Poster Session Time: 11:45 a.m. – 2:15p.m.
Session Type: AAIC :Poster Presentation
Proposal Number: 45398
Presentation Title: Employing Lymphocyte Proliferation as a means to Asses Cell Cycle Dys-regulation in Cognitively Impaired Subjects: Analytical Performance of the LymPro Assay
Poster Number: P3-117

About LymPro Test

The Lymphocyte Proliferation Test (LymPro Test ®) is a diagnostic blood test that measures the ability of peripheral blood lymphocytes to withstand an external stimulation inducing them to enter the cell cycle. It is hypothesized that certain diseases are the result of a compromised cellular machinery that leads to abhorrent cell cycle re-entry by neurons. The inventive step for LymPro involves using peripheral blood lymphocytes (PBLs) as a surrogate for neuronal cell function, suggesting a common immune-based relationship between PBLs and neurons in the brain. LymPro Test ® is currently being developed as a diagnostic blood test for Alzheimer's disease and is being evaluated as a diagnostic blood test for Traumatic Brain injury and Chronic Traumatic Encephalopathy.

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready small molecule indicated for Parkinson's Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amarantus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please visit, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

CONTACT: Amarantus Bioscience Holdings, Inc.:
         Aimee Boutcher, Investor Relations
         408.737.2734 x 101

Amarantus BioScience Holdings, Inc. Logo

Source: Amarantus BioScience Holdings, Inc.